Bevacizumab for blinding eye disease – is it time for the PBS to list for off-label use?
Peter Heyworth
A *
A Lishman Health Foundation, 115 Beach Road, Bunbury, WA 6230, Australia.
Australian Health Review 46(2) 150-152 https://doi.org/10.1071/AH21379
Submitted: 13 September 2021 Accepted: 16 December 2021 Published: 23 March 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of AHHA.
Abstract
Anti-vascular endothelial growth factor eye injections have become the most accepted and effective treatment for some of the leading causes of blindness. Aflibercept (Eylea; Bayer) is the most expensive item on the Pharmaceutical Benefits Scheme, (PBS) with ranibizumab (Lucentis; Roche/Novartis) ranked eighth. In 2011 the pharmaceutical cost for these treatments was A$237 million – now the figure is A$665 million and climbing. Bevacizumab (Avastin; Roche) is part of the original molecular lineage for a group of biologic agents, which were originally designed for cancer therapy. It is now administered worldwide on an off-label basis and in very large numbers for retinal vascular disease. It has a proven efficacy and safety profile. Bevacizumab is thirty times cheaper than the Therapeutic Goods Administration (TGA)-approved alternatives and its use could reduce PBS costs by hundreds of millions of dollars. Should the TGA be the sole arbiter in the approval of drugs, or should alternative bodies have some say in the approval of off-label usage under such compelling circumstances? Legislation for this approach has been approved in France, the UK, and Italy. Only by eliminating the legal risk to authorising bodies and physicians, and the financial disincentive to the patient associated with off-label use, will drugs such as bevacizumab be more widely adopted.
Keywords: age-related macular degeneration, bevacizumab (Avastin), cost, diabetic macular oedema, intra-vitreal injections, off-label, value, pharmaceutical, PBS.
References
[1] Harvey KJ, Day RO, Campbell WG, Lipworth W. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust 2011; 194 567–568.| Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?Crossref | GoogleScholarGoogle Scholar | 21644867PubMed |
[2] Top 10 drugs 2020–21. Aust Prescr 2021; 44 205
| Top 10 drugs 2020–21.Crossref | GoogleScholarGoogle Scholar | 35002034PubMed |
[3] Top 10 drugs 2012–13. Austr Prescr 2012; 35 69
| Top 10 drugs 2012–13.Crossref | GoogleScholarGoogle Scholar |
[4] Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration. Findings of a multicountry study. Arch Ophthalmol 2007; 125 1249–1254.
| Burden and health care resource utilization in neovascular age-related macular degeneration. Findings of a multicountry study.Crossref | GoogleScholarGoogle Scholar | 17846366PubMed |
[5] Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153 209–213.e2.
| Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010.Crossref | GoogleScholarGoogle Scholar | 22264944PubMed |
[6] Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol 2020; 138 40–47.
| Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States.Crossref | GoogleScholarGoogle Scholar | 31725830PubMed |
[7] The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Engl J Med 2011; 364 1897–1908.
| Ranibizumab and bevacizumab for neovascular age-related macular degeneration.Crossref | GoogleScholarGoogle Scholar |
[8] Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying G-S, Jaffe GJ, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016; 123 1751–1761.
| Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials.Crossref | GoogleScholarGoogle Scholar | 27156698PubMed |
[9] Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 2017; 317 2072–2087.
| Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial.Crossref | GoogleScholarGoogle Scholar | 28492910PubMed |
[10] The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372 1193–1203.
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.Crossref | GoogleScholarGoogle Scholar | 25692915PubMed |
[11] Nawrat A. NHS wins landmark ruling against pharm companies over AMD drugs. Pharmaceutical Technology, 21 September 2018. Available at https://www.pharmaceutical-technology.com/news/nhs-landmark-ruling-against-companies-amd/
[12] Landmark Chambers. Supreme Court ends legal challenges over lawfulness of using Avastin Off-label to treat NHS wet AMD patients. Landmark Chambers, 13 November 2020. Available at https://www.landmarkchambers.co.uk/resource-post/supreme-court-ends-legal-challenges-over-lawfulness-of-using-avastin-off-label-to-treat-nhs-wet-amd-patients/
[13] National Institute for Health and Care Excellence (NICE). Age-related macular degeneration: NICE guideline (NG82). NICE; 2018.
[14] Dickson N. The GMC’s stance on Avastin. BMJ 2015; 350 h2043
| The GMC’s stance on Avastin.Crossref | GoogleScholarGoogle Scholar | 25898987PubMed |
[15] Zulli A, Tosoni L. Italian Medicines Agency modifies its decision on Avastin while EU Pharamaceutical Trade Association file a complaint against Italian off label legislation. Resource ID 3-606-5710. Thomson Reuters Practical Law; 2015. Available at https://uk.practicallaw.thomsonreuters.com/3-606-5710?transitionType=Default&contextData=(sc.Default)
[16] Terzieva A. France authorises cheap cancer drug for expensive eye care. Politico, 25 March 2015. Available at https://www.politico.eu/article/france-authorises-cheap-cancer-drug-for-expensive-eye-care/
[17] Miller J. France fines Roche, Novartis 444 million euros in ongoing eye clash. Reuters, 9 September 2020. Available at https://www.reuters.com/article/us-novartis-roche-lucentis-idUSKBN2601SD
[18] Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration a randomized clinical trial. JAMA Ophthalmol 2021; 139 68–76.
| Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration a randomized clinical trial.Crossref | GoogleScholarGoogle Scholar | 33211076PubMed |
[19] Bressler N, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, Vajas A, Papp A, Vogt G, Luu J, Matuskov V, Yoon Y, Pregun T, Kim T, Shin D, Oh I, Jeong H, Yeeun Ki M. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol 2021;
| Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.Crossref | GoogleScholarGoogle Scholar | 34656987PubMed |
